Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Capital Expenditures (2017 - 2025)

STRATA Skin Sciences' Capital Expenditures history spans 11 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, Capital Expenditures rose 1541.94% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $1.7 million, down 41.75%, while the annual FY2024 figure was $1.6 million, 67.4% down from the prior year.
  • Capital Expenditures for Q3 2025 was $1.0 million at STRATA Skin Sciences, up from -$61000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.5 million in Q3 2021 and bottomed at -$740000.0 in Q2 2021.
  • The 5-year median for Capital Expenditures is $725000.0 (2024), against an average of $800000.0.
  • The largest annual shift saw Capital Expenditures plummeted 136.81% in 2023 before it skyrocketed 1541.94% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $1.1 million in 2021, then soared by 50.35% to $1.7 million in 2022, then grew by 1.12% to $1.7 million in 2023, then tumbled by 70.66% to $504000.0 in 2024, then surged by 101.98% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for SSKN's Capital Expenditures are $1.0 million (Q3 2025), -$61000.0 (Q2 2025), and $199000.0 (Q1 2025).